A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

NCT00623428 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

235

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: peginterferon alfa-2a
DRUG: Ribavirin

Sponsor

Hoffmann-La Roche